These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 26945007

  • 1. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J, Read ML, Hoffman J, Brown R, Bradshaw B, Campbell C, Cole T, Navas JD, Eatock F, Gundara JS, Lian E, Mcmullan D, Morgan NV, Mulligan L, Morrison PJ, Robledo M, Simpson MA, Smith VE, Stewart S, Trembath RC, Sidhu S, Togneri FS, Wake NC, Wallis Y, Watkinson JC, Maher ER, McCabe CJ, Woodward ER.
    Hum Mol Genet; 2016 May 01; 25(9):1836-45. PubMed ID: 26945007
    [Abstract] [Full Text] [Related]

  • 2. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.
    Colombo C, Minna E, Rizzetti MG, Romeo P, Lecis D, Persani L, Mondellini P, Pierotti MA, Greco A, Fugazzola L, Borrello MG.
    Orphanet J Rare Dis; 2015 Mar 01; 10():25. PubMed ID: 25887804
    [Abstract] [Full Text] [Related]

  • 3. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients.
    Long KL, Etzel C, Rich T, Hyde S, Perrier ND, Graham PH, Lee JE, Hu MI, Cote GJ, Gagel R, Grubbs EG.
    Fam Cancer; 2017 Apr 01; 16(2):283-289. PubMed ID: 27864651
    [Abstract] [Full Text] [Related]

  • 4. M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.
    Martins-Costa MC, Cunha LL, Lindsey SC, Camacho CP, Dotto RP, Furuzawa GK, Sousa MS, Kasamatsu TS, Kunii IS, Martins MM, Machado AL, Martins JR, Dias-da-Silva MR, Maciel RM.
    Endocr Relat Cancer; 2016 Dec 01; 23(12):909-920. PubMed ID: 27807060
    [Abstract] [Full Text] [Related]

  • 5. Genotype-specific progression of hereditary medullary thyroid cancer.
    Machens A, Lorenz K, Weber F, Dralle H.
    Hum Mutat; 2018 Jun 01; 39(6):860-869. PubMed ID: 29656518
    [Abstract] [Full Text] [Related]

  • 6. The relationship of cytomorphology of medullary thyroid carcinomas between family members with the same RET proto-oncogene mutation.
    Chang JS, Chang CF, Yang WS, Chang TC.
    Acta Cytol; 2011 Jun 01; 55(6):556-62. PubMed ID: 22156466
    [Abstract] [Full Text] [Related]

  • 7. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L, Carlomagno F, Bisceglia M, Anaganti S, Ferretti E, Verrienti A, Arturi F, Scarpelli D, Russo D, Santoro M, Filetti S.
    J Clin Endocrinol Metab; 2006 Mar 01; 91(3):754-9. PubMed ID: 16384843
    [Abstract] [Full Text] [Related]

  • 8. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ, Rodrigues F, Figueiredo P, Naidenov P, Soares P, Bugalho MJ, Lacerda M, Campos B, Martins TC.
    Clin Endocrinol (Oxf); 2006 Jun 01; 64(6):659-66. PubMed ID: 16712668
    [Abstract] [Full Text] [Related]

  • 9. RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.
    Qi XP, Zhao JQ, Chen ZG, Cao JL, Du J, Liu NF, Li F, Sheng M, Fu E, Guo J, Jia H, Zhang YM, Ma JM.
    Oncotarget; 2015 Oct 20; 6(32):33993-4003. PubMed ID: 26356818
    [Abstract] [Full Text] [Related]

  • 10. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
    Wang J, Zhang B, Liu W, Zhang Y, Di X, Yang Y, Yan D.
    Fam Cancer; 2016 Jan 20; 15(1):99-104. PubMed ID: 26254625
    [Abstract] [Full Text] [Related]

  • 11. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M.
    Am J Pathol; 2004 Aug 20; 165(2):511-21. PubMed ID: 15277225
    [Abstract] [Full Text] [Related]

  • 12. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
    Barletta JA, Nosé V, Sadow PM.
    Endocr Pathol; 2021 Mar 20; 32(1):35-43. PubMed ID: 33492588
    [Abstract] [Full Text] [Related]

  • 13. Molecular advances in medullary thyroid cancer diagnostics.
    Hubner RA, Houlston RS.
    Clin Chim Acta; 2006 Aug 20; 370(1-2):2-8. PubMed ID: 16519882
    [Abstract] [Full Text] [Related]

  • 14. Rare RET Variant p.D707E in a Chinese Pedigree with Hereditary Medullary Thyroid Carcinoma.
    Zhang L, Li X, Li Q, Ge S, Chen M, Huang S, Chen B, Li P, Teng B, Xu J, Zhao S, Qi F, Zhang Y.
    Pathobiology; 2017 Aug 20; 84(3):152-160. PubMed ID: 27798940
    [Abstract] [Full Text] [Related]

  • 15. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ, Yüksel B, Tuna MM, Navdar Başaran M, Akkurt Kocaeli A, Ertörer ME, Aydın K, Güldiken S, Şimşek Y, Cihan Karaca Z, Yılmaz M, Aktürk M, Anaforoğlu İ, Kebapçı N, Duran C, Taşlıpınar A, Kulaksızoğlu M, Gürsoy A, Dağdelen S, Erdoğan MF.
    J Clin Res Pediatr Endocrinol; 2016 Mar 05; 8(1):13-20. PubMed ID: 26758973
    [Abstract] [Full Text] [Related]

  • 16. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
    Sarika HL, Papathoma A, Garofalaki M, Vasileiou V, Vlassopoulou B, Anastasiou E, Alevizaki M.
    Clin Endocrinol (Oxf); 2012 Dec 05; 77(6):857-62. PubMed ID: 22676047
    [Abstract] [Full Text] [Related]

  • 17. Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course.
    Kaczmarek-Ryś M, Ziemnicka K, Pławski A, Budny B, Michalak M, Hryhorowicz S, Hoppe-Gołębiewska J, Boruń P, Gołąb M, Czetwertyńska M, Sromek M, Szalata M, Ruchała M, Słomski R.
    Endocr Relat Cancer; 2018 Apr 05; 25(4):421-436. PubMed ID: 29386230
    [Abstract] [Full Text] [Related]

  • 18. Current understanding and management of medullary thyroid cancer.
    Roy M, Chen H, Sippel RS.
    Oncologist; 2013 Apr 05; 18(10):1093-100. PubMed ID: 24037980
    [Abstract] [Full Text] [Related]

  • 19. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
    Romei C, Tacito A, Molinaro E, Agate L, Bottici V, Viola D, Matrone A, Biagini A, Casella F, Ciampi R, Materazzi G, Miccoli P, Torregrossa L, Ugolini C, Basolo F, Vitti P, Elisei R.
    Clin Endocrinol (Oxf); 2015 Jun 05; 82(6):892-9. PubMed ID: 25440022
    [Abstract] [Full Text] [Related]

  • 20. RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family.
    Qi XP, Ma JM, Du ZF, Ying RB, Fei J, Jin HY, Han JS, Wang JQ, Chen XL, Chen CY, Liu WT, Lu JJ, Zhang JG, Zhang XN.
    PLoS One; 2011 Jun 05; 6(5):e20353. PubMed ID: 21655256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.